Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries

被引:54
作者
Adams, Abbie M.
Harding, Penny L.
Iversen, Patrick L.
Coleman, Catherine
Fletcher, Sue
Wilton, Steve D. [1 ]
机构
[1] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia
[2] AVI BioPharma, Corvallis, OR USA
来源
BMC MOLECULAR BIOLOGY | 2007年 / 8卷
关键词
MDX MOUSE; MUSCULAR-DYSTROPHY; EXPRESSION; MODEL; RNA; DELIVERY; INHIBITION; STRATEGIES; OLIGOMERS; MUTATION;
D O I
10.1186/1471-2199-8-57
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Antisense oligonucleotides ( AOs) can interfere with exon recognition and intron removal during pre-mRNA processing, and induce excision of a targeted exon from the mature gene transcript. AOs have been used in vitro and in vivo to redirect dystrophin pre-mRNA processing in human and animal cells. Targeted exon skipping of selected exons in the dystrophin gene transcript can remove nonsense or frame- shifting mutations that would otherwise have lead to Duchenne Muscular Dystrophy, the most common childhood form of muscle wasting. Results: Although many dystrophin exons can be excised using a single AO, several exons require two motifs to be masked for efficient or specific exon skipping. Some AOs were inactive when applied individually, yet pronounced exon excision was induced in transfected cells when the AOs were used in select combinations, clearly indicating synergistic rather than cumulative effects on splicing. The necessity for AO cocktails to induce efficient exon removal was observed with 2 different chemistries, 2'-O-methyl modified bases on a phosphorothioate backbone and phosphorodiamidate morpholino oligomers. Similarly, other trends in exon skipping, as a consequence of 2'-O-methyl AO action, such as removal of additional flanking exons or variations in exon skipping efficiency with overlapping AOs, were also seen when the corresponding sequences were prepared as phosphorodiamidate morpholino oligomers. Conclusion: The combination of 2 AOs, directed at appropriate motifs in target exons was found to induce very efficient targeted exon skipping during processing of the dystrophin pre-mRNA. This combinatorial effect is clearly synergistic and is not influenced by the chemistry of the AOs used to induce exon excision. A hierarchy in exon skipping efficiency, observed with overlapping AOs composed of 2'-O-methyl modified bases, was also observed when these same sequences were evaluated as phosphorodiamidate morpholino oligomers, indicating design parameters established with one chemistry may be applied to the other.
引用
收藏
页数:8
相关论文
共 39 条
  • [1] Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: Indication for steric hindrance of SR protein binding sites
    Aartsma-Rus, A
    De Winter, CL
    Janson, AAM
    Kaman, WE
    Van Ommen, GJB
    Den Dunnen, JT
    van Deutekom, JCT
    [J]. OLIGONUCLEOTIDES, 2005, 15 (04) : 284 - 297
  • [2] Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
    Aartsma-Rus, A
    Janson, AAM
    Kaman, WE
    Bremmer-Bout, M
    den Dunnen, JT
    Baas, F
    van Ommen, GJB
    van Deutekom, JCT
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (08) : 907 - 914
  • [3] Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells
    Aartsma-Rus, A
    Kaman, WE
    Bremmer-Bout, M
    Janson, AAM
    den Dunnen, JT
    van Ommen, GJB
    van Deutekom, JCT
    [J]. GENE THERAPY, 2004, 11 (18) : 1391 - 1398
  • [4] Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers
    Alonso, M
    Stein, DA
    Thomann, E
    Moulton, HM
    Leong, JC
    Iversen, P
    Mourich, DV
    [J]. JOURNAL OF FISH DISEASES, 2005, 28 (07) : 399 - 410
  • [5] Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
    Alter, J
    Lou, F
    Rabinowitz, A
    Yin, HF
    Rosenfeld, J
    Wilton, SD
    Partridge, TA
    Lu, QL
    [J]. NATURE MEDICINE, 2006, 12 (02) : 175 - 177
  • [6] Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
    Amantana, A
    Iversen, PL
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (05) : 550 - 555
  • [7] Neutrally charged phosphorodiamidate morpholino antisense oligomers: Uptake, efficacy and pharmacokinetics
    Arora, V
    Devi, GR
    Iversen, PL
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (05) : 431 - 439
  • [8] Arora V, 2000, J PHARMACOL EXP THER, V292, P921
  • [9] RNA interference in mammalian cells by chemically-modified RNA
    Braasch, DA
    Jensen, S
    Liu, YH
    Kaur, K
    Arar, K
    White, MA
    Corey, DR
    [J]. BIOCHEMISTRY, 2003, 42 (26) : 7967 - 7975
  • [10] Targeted exon skipping in transgenic hDMD mice:: A model for direct preclinical screening of human-specific antisense oligonucleotides
    Bremmer-Bout, M
    Aartsma-Rus, A
    de Meijer, EJ
    Kaman, WE
    Janson, AAM
    Vossen, RHAM
    van Ommen, GJB
    den Dunnen, JT
    van Deutekom, JCT
    [J]. MOLECULAR THERAPY, 2004, 10 (02) : 232 - 240